OncoMatch/Clinical Trials/NCT05173272
Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer
Is NCT05173272 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Neoadjuvant Therapy for cervical cancer.
Treatment: Neoadjuvant Therapy — The main objective of this study is to determine whether neoadjuvant chemotherapy combined with slulimumab sequential concurrent chemoradiotherapy versus concurrent chemoradiotherapy for locally advanced cervical cancer could improve progression-free survival rates. Women in the experimental arm will receive neoadjuvant chemotherapy (cisplatin plus paclitaxel) combined with slulimumab every 21 days during 2 cycles followed by concurrent chemoradiation therapy. Women in the control arm will receive concurrent chemoradiation therapy alone. 286 patients will be recruited during 2 years, with 3 years of follow up period.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Cervical Cancer
Disease stage
Required: Stage FIGO 2018 IB3, FIGO 2018 II, FIGO 2018 IIIA, FIGO 2018 IIIB, FIGO 2018 IIIC1, FIGO 2018 IIIC2 (FIGO 2018)
FIGO 2018 Ib3-IIIc2
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Lab requirements
Blood counts
ANC1.5d710^9/L, platelet count100d710^9/L, Hb90g/L, WBC3.0d710^9/L, and no bleeding tendency
Kidney function
Serum creatinine (Cr) 1.5 d7 ULN or endogenous creatinine clearance 50mL/min
Liver function
Total bilirubin (TBIL)1.5d7ULN (Gilbert syndrome allows 5d7ULN); ALT and AST 142.5d7ULN
Cardiac function
left ventricular ejection fraction (LVEF) 50%
No obvious signs of hematological diseases, ANC1.5d710^9/L, platelet count100d710^9/L, Hb90g/L, WBC3.0d710^9/L, and no bleeding tendency before enrollment; Adequate hepato-renal function is needed, including: Total bilirubin (TBIL)1.5d7ULN (Gilbert syndrome allows 5d7ULN) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 142.5d7ULN Serum creatinine (Cr) 1.5 d7 ULN or endogenous creatinine clearance 50mL/min; Cardiac Function: left ventricular ejection fraction (LVEF) 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05173272 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage FIGO 2018 IB3 or FIGO 2018 II or FIGO 2018 IIIA or FIGO 2018 IIIB or FIGO 2018 IIIC1 or FIGO 2018 IIIC2 is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages